153435-63-3Relevant articles and documents
Pyrimidine quinoline derivatives, and preparation method and applications thereof
-
Paragraph 0120; 0122; 0127-0128, (2019/10/01)
The invention discloses pyrimidine quinoline derivatives, a prodrug, and preparation method and applications thereof. The structure of the pyrimidine quinoline derivatives is represented by formula I, wherein R1 is used for representing hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C4-7 heterocyclic aryl, C4-7 substituted heterocyclic aryl, benzyl, or substituted benzyl, glycosyl, and amino acid; R2, R3, R4, and R5 are used for independently representing hydrogen, C1-4 alkyl, C1-4 alkyloxy, hydroxyl, amino, or substituted amino, C1-4 halogenated alkyl or halogen, glycosyl, and amino acid; R6 is used for representing substituted or non-substituted five-membered heterocycle, substituted or non-substituted six-membered heterocycle, substituted or non-substituted C8-12 fused heterocycle. The pyrimidine quinoline derivatives possess excellent inhibition effect on five kinds of cancer cells, the inhibition IC50 value of most compounds is lower than 20M, the IC50 value of a part of the compounds is even lower than 5M, the inhibition effect is extremely obvious, and the compounds can be prepared into anti-tumor drugs for applications.
Phenanthroline compound and organic light emitting element comprising the same
-
Paragraph 0071; 0072-0074, (2018/09/02)
The present invention relates to a phenanthroline compound and an organic electroluminescent device exhibiting excellent efficiency characteristics by including the compound in one or more organic layers. The phenanthroline compound is represented by chemical formula 1. In chemical formula 1, X_1 and X_2 are nitrogen, Ar is a chemical bond, a phenyl group, a naphthalene group, a biphenyl group, a pyridine group or a quinoline group, and L is a chemical bond, a phenyl group, a naphthalene group, a biphenyl group, a pyridine group, or a quinoline group.COPYRIGHT KIPO 2018
SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION
-
Page/Page column 74, (2011/02/24)
The invention concerns a spiro-amino compound of Formula (Vl) wherein m is 1 or 2 or 3, n is 1 or 2, R is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, halogen, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, phenyl optionally substituted with one or more halogen atoms, a 5- or 6-membered heterocycle comprising at least one nitrogen atom; P is a substituent Q or COQ, wherein Q is selected from the group consisting of phenyl, pyridil, pyrimidil, quinolyl, isoquinolyl, quinoxalyl, benzofuranyl, imidazotriazolyl, being such Q optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, carbammido, methylcarbammido, carboxy, methylcarboxy or a pharmaceutically acceptable salt thereof.
COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
Page/Page column 58; 77; 95, (2010/11/24)
The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.
Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
-
Page 101; 105, (2008/06/13)
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
-
, (2008/06/13)
Novel compounds of the formula wherein R is optionally substituted heteroaryl or R1 is H or C1—C6 alkyl; and R2 and R3 are —CH3, —OCH3 or halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.
Quinuclidine compounds and drugs containing the same as the active ingredient
-
, (2008/06/13)
The present invention provides an excellent squalene synthesizing enzyme inhibitor. Specifically, it provides a compound (I) represented by the following formula, a salt thereof or a hydrate of them. In which R1 represents (1) hydrogen atom or (2) hydroxyl group; HAr represents an aromatic heterocycle which may be substituted with 1 to 3 groups; Ar represents an optionally substituted aromatic ring; W represents a chain represented by (1) —CH2—CH2— which may be substituted, (2) —CH=CH— which may be substituted, (3) —C≡C—, (4) —NH—CO—, (5) —CO—NH—, (6) —NH—CH2—, (7) —CH2—NH—, (8) —CH2—CO—, (9) —CO—CH2—, (10) —NH—S(O)l—, (11) —S(O)l—NH—, (12) —CH2—S(O)— or (13) —S(O)l—CH2— (l denotes 0, 1 or 2); and X represents a chain represented by (1) a single bond, (2) an optionally substituted C1-6 alkylene chain, (3) an optionally substituted C2-6 alkenylene chain, (4) an optionally substituted C2-6 alkynylene chain, (5) a formula —Q— (wherein Q represents oxygen atom, sulfur atom, CO or N(R2) (wherein R2 represents a C1-6 alkyl group or a C1-6 alkoxy group)), (6) —NH—CO—, (7) —CO—NH—, (8) —NH—CH2—, (9) —CH2—NH—, (10) —CH2—CO—, (11) —CO—CH2—, (12) —NH—S(O)m—, (13) —S(O)m—NH—, (14) —CH2—S(O)m—, (15) —S(O)m—CH2— (wherein m denotes 0, 1 or 2) or (16) —(CH2)n—O— (wherein n denotes an integer from 1 to 6).
